Pancreatic Cancer Drug Heralds a Paradigm Shift: Lisa Jarvis

It’s not often that you see a standing ovation at a medical conference. But over the weekend, a ballroom full of cancer specialists got to their feet to applaud a slide showing that Revolution Medicine’s daraxonrasib had doubled the survival time of patients with pancreatic cancer.

The response shows the pent-up desperation for progress in one of the toughest-to-treat cancers. And daraxonrasib represents more than progress. It feels more like a paradigm shift.

“It changes everyone’s perception of what you can do for this disease — how you can help people,” says Brian Wolpin, the Dana-Farber Cancer Institute oncologist who ...